Prelude Capital Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Prelude Capital Management’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$477K	Buy	50,826 +33,045	+186%	+$278K	0.04%	533
2025 Q4	$145K	Sell	17,781 -49,203	-73%	-$607K	0.01%	1133
2025 Q3	$847K	Sell	66,984 -13,363	-17%	-$127K	0.07%	345
2025 Q2	$554K	Hold	80,347	–	–	0.05%	405
2025 Q1	$427K	Buy	+80,347	New	+$709K	0.03%	567
2024 Q3	–	Sell	-14,446	Closed	-$654K	–	1323
2024 Q2	$654K	Sell	14,446 -3,500	-20%	-$147K	0.05%	429
2024 Q1	$704K	Buy	+17,946	New	+$443K	0.04%	491

Other funds holding CRBP

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Prelude Capital Management's CRBP Position: Q1 2026 in Review

Prelude Capital Management increased its Corbus Pharmaceuticals (CRBP) stake by 186% in Q1 2026, buying an estimated $278K and bringing the position to 50,826 shares worth $477K. The position accounts for 0.04% of the portfolio, ranked #533.

Prelude Capital Management first reported a position in CRBP in Q1 2024 and has held it in 7 quarters since. The position peaked at $847K in Q3 2025. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

Prelude Capital Management held 50,826 shares of Corbus Pharmaceuticals worth $477K as of Q1 2026.
Prelude Capital Management bought 33,045 Corbus Pharmaceuticals shares in Q1 2026, an estimated $278K.
Corbus Pharmaceuticals made up 0.04% of Prelude Capital Management's portfolio in Q1 2026, its #533 holding.
Prelude Capital Management first reported a position in Corbus Pharmaceuticals in Q1 2024 and has held it in 7 quarters since.
Prelude Capital Management's Corbus Pharmaceuticals position peaked at $847K in Q3 2025.
107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.